A new trading day began on Monday, with 4D Molecular Therapeutics Inc (NASDAQ: FDMT) stock price up 8.65% from the previous day of trading, before settling in for the closing price of $8.9. FDMT’s price has ranged from $2.23 to $10.03 over the past 52 weeks.
Healthcare Sector giant saw their annual sales slid by -9.89% over the last five years. Meanwhile, its annual earnings per share averaged -23.95%. With a float of $42.62 million, this company’s outstanding shares have now reached $46.70 million.
The firm has a total of 227 workers. Let’s measure their productivity.
4D Molecular Therapeutics Inc (FDMT) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of 4D Molecular Therapeutics Inc is 8.75%, while institutional ownership is 81.98%. The most recent insider transaction that took place on Sep 23 ’25, was worth 19,256. In this transaction Chief Legal Officer of this company sold 2,407 shares at a rate of $8.00, taking the stock ownership to the 7,596 shares. Before that another transaction happened on Sep 23 ’25, when Company’s Officer proposed sale 7,312 for $7.40, making the entire transaction worth $54,109.
4D Molecular Therapeutics Inc (FDMT) Earnings and Forecasts
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.79 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.89 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -23.95% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -9.91% during the next five years compared to -9.89% drop over the previous five years of trading.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
Here are 4D Molecular Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 15053.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.71, a number that is poised to hit -0.98 in the next quarter and is forecasted to reach -3.81 in one year’s time.
